PolyPid Ltd. (NASDAQ: PYPD) is a late-stage biopharmaceutical company developing innovative therapies designed to improve surgical outcomes and reduce post-operative complications. The company’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology enables the controlled and prolonged release of therapeutics directly at the surgical site. Its lead product candidate, D-PLEX₁₀₀, is being developed to help prevent surgical site infections, a significant challenge for healthcare systems worldwide.

Topics discussed include the advancement of D-PLEX₁₀₀, the company’s proprietary drug delivery platform, clinical development progress, market opportunities, and PolyPid’s long-term growth strategy.

This company webcast was recorded during the Lytham Partners Spring 2026 Investor Conference.